logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
BackJournal Details
Expert Opinion on Drug Safety cover

Expert Opinion on Drug Safety

IF3.1
Papers2763
Citations5299
Journal Papers 2769
Publication Date
delete
Long-term safety of treatment of hemophilia A: a comprehensive review
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-09-30
delete0
PREAI
deleteJohnny Mahlangu
deleteShare
deleteSave
Tolerance of methotrexate co-administered with pegloticase in patients with uncontrolled gout: overview of the findings from the mirror RCT
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-09-16
delete0
PREAI
deleteVinicius Domingues; Abdul Abdellatif; Alexis Woods; Quinnie Yang; Michael E. Weinblatt; Junzhi Ji; Brad Marder; Brian LaMoreaux
deleteShare
deleteSave
A safety review of jak inhibitors for managing alopecia areata
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-09-15
delete0
PREAI
deleteKanchalit Thanomkitti; Sofia Spagnolini; Antonella Tosti
deleteShare
deleteSave
Safety of treatments for children with functional constipation
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-08-24
delete0
PREAI
deleteTirza M. van Os; Megan A. Read; Richard J. Wood; Carlo Di Lorenzo; Marc A. Benninga; Peter L. Lu
deleteShare
deleteSave
Lesser-known medication safety considerations in sickle cell disease
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-08-19
delete0
deleteOAAI
deleteNajbah Galadanci; Julie Kanter
deleteShare
deleteSave
Myositis in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-017 systematic review and meta-analysis
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-08-14
delete0
PREAI
deleteElsa Vitale; Gerardo Cazzato; Lorenza Maistrello; Mario Della Mura; Mauro Francesco Pio Maiorano; Francesco Ciccimarra; Oronzo Brunetti; Concetta Calabrò; Brigida Anna Maiorano; Fernando Sabino Marques Monteiro; Enes Erul; Francesco Massari; Alessandro Rizzo; Matteo Santoni
deleteShare
deleteSave
Safety profile of dual TIGIT and PD-L1 blockade with tiragolumab plus atezolizumab in solid tumors: a systematic review and meta-analysis of randomized controlled trials
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-08-12
delete0
deleteOAAI
deleteZaher Mutaz Ashour; Mus’ab Theeb Mustafa; Osama Wadah Rammaha; Abdallah Moh’d Said Hamdan; Yihea Mohammad Al-Mashaqbah; Abdallah Yaser Alasmar; Lou’y Ahmed Al-Rabaeh; Mohammad AlElaimat; Ayham Omar Khalifah; Omar Jamal Ramadan; Aws Khalid Abushanab; Abdulqadir J. Nashwan
deleteShare
deleteSave
Long-term efficacy and safety of intra-articular corticosteroid injections in patients with knee osteoarthritis
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-07-21
delete0
deleteOAAI
deleteAricia J. Thirumaran; David J. Hunter
deleteShare
deleteSave
Safety of Janus kinase inhibitors in patients with moderate-to-severe atopic dermatitis: a systematic review and meta-analysis of observational studies
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-07-16
delete0
PREAI
deleteMei Li; Jianing Ni; Lian Zhang; Can Chen; Jingjing Ye; Ninggang Chen
deleteShare
deleteSave
Exploring the safety and efficacy of DOACs in clinically complex phenotypes of patients with atrial fibrillation: focus on frailty, multimorbidity and polypharmacy
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-07-12
delete0
PREAI
deletePanteleimon E. Papakonstantinou; Gregory Y. H. Lip
deleteShare
deleteSave
Trigger tool methodologies in hospital settings: reappraising their role in pharmacovigilance and digital safety surveillance
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-07-10
delete0
PREAI
deleteMarija Ilic; Dejana Krajacic; Marina Blagojevic; Milica Paut Kusturica; Jovanka Kolarovic; Djendji Siladji; Nebojsa Stilinovic; Aleksandar Raskovic
deleteShare
deleteSave
Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-06-30
delete0
PREAI
deleteTiffany R. Price; Chia-Yuan Chang; Kirya Skinner; Michael Dinneny; Parmida Nafezi; Lisa Kuramoto; Mary A. De Vera; Neil R. Cashman; Jacquelyn J. Cragg
deleteShare
deleteSave
Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-06-24
delete0
PREAI
deleteTerry J. Smith
deleteShare
deleteSave
A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-06-09
delete0
PREAI
deleteSiddhartha Dutta; Rima Shah; Shubha Singhal; Mamta Singh; Sagar Dholariya; Shalini Chawla; Chandan Katoch
deleteShare
deleteSave
Tirzepatide data: safety first is safety always!
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-06-02
delete0
PREAI
deleteMiodrag Janić; Syed Arman Rabbani; Mohamed El-Tanani; Imran Rangraze; Andrej Janež; Viviana Maggio; Manfredi Rizzo
deleteShare
deleteSave
An update on the safety of biologics for the treatment of psoriasis
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-05-22
delete0
PREAI
deleteVictoria McGuirt; Hiral Patel; Maia Davis; Steven Feldman
deleteShare
deleteSave
Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-05-17
delete0
PREAI
deleteLiyi Chen; Guo-Hui Li; Chun-Yu Li
deleteShare
deleteSave
Long-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-05-04
delete0
PREAI
deleteSelin Akturk Esen; Dogan Uncu; Mehmet Ali Nahit Sendur
deleteShare
deleteSave
Safety of anti-IL-5 compounds for the treatment of eosinophilic asthma with a focus on special populations
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-05-01
delete0
PREAI
deleteCaminati, Marco; Gagliani, Claudia; Bondi, Benedetta; Bagnasco, Diego; Vijverberg, Susanne J. H.; Zurlo, Marco; Maule, Matteo; Principe, Stefania
deleteShare
deleteSave
A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications
deleteExpert Opinion on Drug Safety
IF3.1
delete2026-04-30
delete0
PREAI
deleteBrad Jordan; Luke Arbogast; Matthew Clemens; Lihua Huang; Matthew Snyder
deleteShare
deleteSave